Clinical trial
Tocilizumab for the Treatment of Behcet's Syndrome
NCT01693653 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tocilizumab for the Treatment of Behcet's Syndrome
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2012
- Completion date
- November 30, 2013
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.